Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe
Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe
While Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated. Today, a molecular genetics diagnostic company specializing in the early detection of cancer, Mainz Biomed NV (NASDAQ:MYNZ) revealed it made an important step on its mission to provide access to one such diagnostic test to people across the globe and by doing so, providing them with a lifechanging head start in their health battle.
尽管辉瑞公司（纽约证券交易所代码：PFE）和Moderna Inc（纳斯达克股票代码：MRNA）在癌症治疗方面取得了长足的进展，但早期发现对抗这种疾病的重要性怎么强调都不为过。今天，一家专门从事癌症早期发现的分子遗传学诊断公司Mainz Biomed NV（纳斯达克股票代码：MYNZ）透露，它在向全球人们提供一种此类诊断测试的使命上迈出了重要的一步，从而为他们在健康之战中提供了一个改变人生的开端。
Mainz Biomed Brings Elevated Cancer Diagnostic Capability To Romania
Mainz Biomed 为罗马尼亚带来了更高的癌症诊断能力
Mainz Biomed just announced it will be launching its flagship product, ColoAlert in Romania. By entering into a strategic partnership with Bioclinica, a national leader in the Romanian healthcare sector, Mainz Biomed has brought a highly effective and user-friendly at-home detection colorectal cancer test to the Romanian population who has one of the highest CRC incidence rates in Europe without having any national screening program in place. With 1.6 million individuals aged 40 to 49 years, 6.1 million in the 50 to 74 years age box and 1.5 million aged over 75 years, the potential market for ColoAlert is substantial, reaching 9.2 million tests per year. everaging the renowned expertise and extensive network of Bioclinica, ColoAlert will immediately become available to a large portion of the Romanian population.
Mainz Biomed刚刚宣布将在罗马尼亚推出其旗舰产品ColoAlert。通过与罗马尼亚医疗保健领域的全国领导者Bioclinica建立战略合作伙伴关系，Mainz Biomed为罗马尼亚人口带来了一种高效且用户友好的居家检测结直肠癌检测，这些人群是欧洲结直肠癌发病率最高的国家之一，但没有任何国家筛查计划。ColoAlert有160万人年龄在40至49岁之间，610万人年龄在50至74岁之间，150万人年龄在75岁以上，ColoAlert的潜在市场是巨大的，每年达到920万次检测。利用Bioclinica的著名专业知识和广泛的网络，ColoAlert将立即向很大一部分罗马尼亚人口开放。
While Europeans make up only one tenth of the world population, they make one fourth of annual cancer cases across the globe. CRC is the second most lethal cancer in Europe and Mainz Biomed's ColoAlert is an important step in addressing this challenge.
虽然欧洲人只占世界人口的十分之一，但他们占全球每年癌症病例的四分之一。结直肠癌是欧洲第二大致命癌症，美因茨生物医学的ColoAlert是应对这一挑战的重要一步。
Innovating Both The Diagnosis And Treatment Landscape Is Essential In Combating Cancer
创新诊断和治疗格局对于抗击癌症至关重要
Back in March, Pfizer bought Seagen, a biological drug developer, for $43 billion to deepen its reach into innovative cancer treatments. Last year, oncology department at Pfizer brought in $12 billion to the revenue table and it had treatments for prostate cancer and breast cancer. With Seagan, Pfizer expanded into treatments for lymph nodes cancer, urinary tract cancer, and colorectal cancer. One year ago, Pfizer deepened its partnership with Erasca in an effort to combine two drugs that complement each other to combat Pancreatic and Colorectal Cancer. mRNA COVID-19 vaccines already saved lives and won a Nobel, as they continue to transform medicine, cancer seems to be the next conquest on their development list.
早在三月份，辉瑞就以430亿美元的价格收购了生物药物开发商Seagen，以深化其在创新癌症治疗方面的影响力。去年，辉瑞的肿瘤部门为收入表带来了120亿美元的收入，并有前列腺癌和乳腺癌的治疗方法。与西根合作，辉瑞将业务扩展到淋巴结癌、尿路癌和结直肠癌的治疗领域。一年前，辉瑞深化了与Erasca的合作伙伴关系，努力结合两种相互补充的药物来对抗胰腺癌和结直肠癌。mRNA COVID-19 疫苗已经挽救了生命并获得了诺贝尔奖，随着它们继续改变医学，癌症似乎是其开发清单上的下一个征服。
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
免责声明：此内容仅供参考。它不打算作为投资建议。